We have synthesized and characterized gold nanoparticles (spheres and rods) with optical extinction bands within the "optical imaging window." The intense plasmon resonant driven absorption and scattering peaks of these nanoparticles make them suitable as contrast agents for optical imaging techniques. Further, we have conjugated these gold nanoparticles to a mouse monoclonal antibody specific to HER2 overexpressing SKBR3 breast carcinoma cells. The bioconjugation protocol uses noncovalent modes of binding based on a combination of electrostatic and hydrophobic interactions of the antibody and the gold surface. We discuss various aspects of the synthesis and bioconjugation protocols and the characterization results of the functionalized nanoparticles. Some proposed applications of these potential molecular probes in the field of biomedical imaging are also discussed.
We have synthesized and characterized gold nanoparticles (spheres and rods) with optical extinction bands within the "optical imaging window." The intense plasmon resonant driven absorption and scattering peaks of these nanoparticles make them suitable as contrast agents for optical imaging techniques. Further, we have conjugated these gold nanoparticles to a mouse monoclonal antibody specific to HER2 overexpressing SKBR3breast carcinoma cells. The bioconjugation protocol uses noncovalent modes of binding based on a combination of electrostatic and hydrophobic interactions of the antibody and the gold surface. We discuss various aspects of the synthesis and bioconjugation protocols and the characterization results of the functionalized nanoparticles. Some proposed applications of these potential molecular probes in the field of biomedical imaging are also discussed.
Optical imaging encompasses a multitude of techniques
for the elucidation of morphology, molecular function, and metabolism of tissue
with the general objective of detecting, diagnosing, staging, and treatment
monitoring of disease. Progression of disease is usually accompanied by changes
in physiology and pathology that are manifested as location-specific changes in
optical properties thereby providing contrast for optical imaging to study
disease.Optical imaging techniques span the range from surface
to bulk imaging systems with applications ranging from “optical biopsies” to
full human breast imaging with resolutions that cover the microscopic to
macroscopic. Some important imaging techniques for superficial tissue imaging
are confocal microscopy [1], two-photon microscopy [2], and optical coherence
tomography (OCT) [3].
Techniques that permit subsurface to deep imaging are diffuse optical imaging
(DOT) [4] and
photoacoustic imaging [5].The interaction of visible and near-infrared (NIR) light
with tissue is dominated byabsorption
processes which are due to the presence of various chromophores such as
hemoglobin, oxy-hemoglobin, melanin, water, and lipids [6];scattering
processes due to the cell membrane and cell structures such as the nucleus,
mitochondria, lysosomes [6].Penetration of light in tissue is dependent on the
extent of the two processes above and is low in the high-energy visible region
of the spectrum. This is due to high absorption by hemoglobin and severe light
scattering. In the wavelength regime between 600 nm and 1100 nm, absorption and
scattering losses are minimal permitting high-light penetration. This is the
so-called “optical imaging window” which is exploited for deep imaging in
tissue [7].The sensitivity and specificity of optical imaging
techniques to visualize a pathological disorder are governed by contrast: the
ability of the disease to differentially scatter or absorb light compared with
nonpathological tissue and background noise. This native or endogenous contrast
may not be sufficient and in any case, the interactions of light with tissue
are not disease-specific. Therefore, there is a role for exogenously
administered contrast enhancing agents which have affinity for the disease site
through biochemical interactions, providing not only sensitive but also
disease-specific signals.Contrast agents for optical imaging thus far have
near-infrared dyes based on cyanine dyes [8] such as Indocyanine Green [9], but in the last few years,
gold nanoparticles [10-12] have emerged as prime candidates due to their unusual
optical properties and inherent biocompatibility.Gold metal nanoparticles (NPs) exhibit narrow and
intense absorption and scattering bands due to the phenomenon of plasmon
resonance. This occurs at the resonance condition of the collective oscillation
that the conduction electrons experience in an electromagnetic field of the
appropriate wavelength [13]. The plasmon resonant condition of gold NPs depends
upon their size, shape, structure (solid or hollow), and upon the refractive
index of the embedding medium. Spherical gold nanoparticles have a single
plasmon resonant extinction peak at around 520 nm, which does not shift
extensively with changes in size and refractive-index of the surrounding
medium. This is a wavelength at which light penetration in tissue is poor due
to strong scattering and absorption by hemoglobin, and gold nanospheres are not
useful in contrast enhancement for deep tissue imaging.Rod-shaped NPs exhibit two plasmon resonances due to
oscillation of the conduction electrons along the short axis as well as along
the long axis of the particles. The former plasmon band is called the
transverse resonance and the latter the longitudinal resonance. While the
transverse plasmon band occurs in the neighborhood of 520 nm, the longitudinal
band is red-shifted. The extent of the red-shift depends on the aspect ratio of
the nanorod; the higher the aspect ratio, the further the shift. Thus by
tailoring the length and/or width of these particles, their extinction peaks
may be made to cover the low-energy visible to infrared wavelength regions.The intense scattering and absorption of light, that
occurs under the plasmon resonant condition coupled with the ability to tune
the resonance into the near-infrared (NIR) by manipulating the aspect ratio,
make gold nanorods extremely attractive as contrast agents for optical imaging
techniques. Further, gold-protein chemistry is well developed and several
bioconjugation protocols are available in the literature, which allows the
combination of the targeting functionality of antibodies with such gold NPs.
The inertness and biocompatibility of gold in general hold promise the use of
gold NPs for in vivo imaging applications.Gold NPs can be synthesized using wet chemical methods
which are based on the reduction of gold salts by reagents such as sodium
borohydride and ascorbic acid. Seed-mediated methods dominate wet chemical
synthesis routes. These involve the reduction of gold using weak reducing
agents onto small nanospheres of gold as seed, in the presence of
shape-directing surfactants usually cetyl trimethylammonium bromide (CTAB).
These methods may be distinguished into those that use silver ion assistance in
growth solutions and those that do not.Murphy and coworkers described the three-step growth
protocol [14, 15], where medium to high
aspect ratio nanorods could be synthesized, without the use of silver nitrate.
Seed particles are generated by reducing gold salt using sodium borohydride in
the presence of sodium citrate. The spheres are coated with a layer of
negatively charged citrate ions that maintain colloid stability against
aggregation by electrostatic repulsion. These spheres seed a growth solution
comprising gold salt, CTAB, and ascorbic acid in three steps thereby slowing
down reduction. The mechanism of nanorod formation by this method is not yet
fully understood. Murphy et al. [15] proposed that the polar CTA+
head group of the surfactant
binds with greater preference to certain crystallographic faces thereby
passivating them to the deposition of gold. The other faces, on the other hand,
would be exposed for gold to be reduced on, thereby producing anisotropic
growth into rods.The methods using silver nitrate in the growth
solutions were proposed by Jana et al. [16], but modified
by Nikoobakht and El-Sayed [17] to achieve spectacular yields of nanorods with
excellent monodispersity. Importantly, they also showed that changing the
quantity of Ag+ ions in the growth solution allows for fine-tuning of the
aspect ratios of the nanorods. The mechanism at work in this protocol has been
debated in the recent past. One mechanism postulates CTAB as a soft template
which elongates on addition of Ag+ ions which occupy regions between the CTA+
head groups to reduce the repulsion between the head groups [17]. A second mechanism invokes
the CTAB passivation concept with additional adsorption of silver bromide on
facets slowing down reduction and producing rods shorter than those made
without using Ag+ [18]. A third mechanism which has appeared recently
[19] proposes the
underpotential deposition of Ag0 on certain faces, followed by CTAB binding,
which serves to stabilize the faces, and allows gold reduction on other faces
resulting in rod formation.In this article, we present our experiences in
synthesizing gold nanospheres and nanorods using slight modifications of the
protocols discussed above. Our goal is to obtain nanorods whose aspect ratios
can be tuned to obtain plasmon peaks between 650 nm–850 nm. Next, we conjugate
the gold nanospheres and gold nanorods to the HER81 monoclonal antibody using
electrostatic and hydrophobic interactions. The conjugation does not use
modifications of the bilayer charge of nanorods nor does it use any linkers. We
discuss various aspects of these protocols and postulate a possible mechanism
for the bioconjugation of the antibody with the gold nanorods. We also discuss
the feasibility of using these molecular probes for contrast enhancement of
photoacoustic cancer imaging using simulations.
2. EXPERIMENTAL SECTION: MATERIALS AND
METHODS
2.1. Gold nanorods using the
silver-assisted single surfactant growth method
As mentioned earlier, the seed-mediated protocol
requires the use of small gold nanospheres to seed growth solutions with silver
nitrate as per the protocol of Nikoobakht and El-Sayed [17].The following are the reagents used for the synthesis
of the gold seed and gold nanorods.Tetrachloroauric acid (HAuCl4 ⋅ 3H2O) was purchased
from Acros Organics (Belgium), hexadecyltrimethylammonium bromide (CTAB
> 99%), sodium
borohydride (NaBH4, 99%), and ascorbic acid (99%) from Aldrich (The
Netherlands) and silver nitrate (AgNO3, 99.8%) from Merck (Germany). Prior to
use, all glassware was cleaned with hydrofluoric acid (HF), further with aqua
regia (HCl/HNO3) and rinsed twice with deionized water.
Gold seed of 3.5 nm diameter
The synthesis was done using protocols of Nikoobakht
and El-Sayed [17] with
slight modifications. A solution of CTAB (5 mL; 0.2 M) was sonicated for 20
minutes at 40°C in a water
bath. A solution of HAuCl4⋅ 3H2O (5 mL; 0.0005 M) was added with continuous
stirring under inert conditions (nitrogen environment). Then, an ice-cold
aqueous solution of NaBH4 (0.6 mL; 0.01 M) was added at once with vigorous
stirring for 1 minute. This seed solution (CTAB-capped) is further used during
growth stage of nanorods.
Gold nanorods of varying aspect ratios
Five identical conical flasks containing 10 mL of a growth solution that consists of CTAB (5 mL; 0.2 M) and HAuCl4 ⋅ 3H2O (5 mL; 0.001 M) were prepared. The color of the growth solution is dark-yellow. AgNO3 (50, 100, 150, 200, and 250 μL of 0.006 M)
was added to the five identical growth solution flasks in an amount that was
chosen so as to yield desired aspect ratios for the resulting nanorods.
Following this, the mild reducing agent ascorbic acid (70
μL; 0.1 M) was added to each growth solution conical flask to give colorless solutions.
Finally, 14 μL of preformed
CTAB-capped seed solution was added to each conical flask, and mixtures were
gently mixed. After 3 hours at 24°C, the nanorod
suspension turned into a dark-blue solution with a brownish opalescence. These
solutions were concentrated by centrifuging twice at 12000 g for 20 minutes
which also enabled removal of the excess unbound CTAB. The centrifuged gold
nanorods which are dispersed in water were stored at 4°c
2.2. Characterization of gold
nanoparticles
Electron microscopy of the NPs was performed using a
CM 30 Philips transmission electron microscope (TEM) or a Zeiss-1550
high-resolution scanning electron microscope (HRSEM). Particle sizes were
estimated using NI Vision module (Labview, National Instruments) on the digital
SEM images with at least 250 particles considered in each case. Extinction
spectra of NPs (and bioconjugated NPs) were measured using the Shimadzu PC3101
UV-Vis-NIR spectrophotometer.The concentration of nanorods synthesized was
estimated using the relation
A = cdε, where
A is the measured
absorbance,
c the
concentration in moles (M),
ε the molar
extinction coefficient (M−1 cm−1), and
d the path length
of the cuvette used to record the spectra. The derived molar extinction
coefficients can be compared with
ε values from a
recent report, estimated for a range of aspect ratios of nanorods by measuring
the gold content in sols using inductively coupled plasma (ICP) atomic emission
spectroscopy [19].
2.3. Bioconjugation of HER81 mAb to gold
nanoparticles
Conjugation was achieved using combination of
electrostatic and hydrophobic binding interactions. The particles chosen for
bioconjugation were 25 nm citrate-capped gold spheres (Aurion, Wageningen, The
Netherlands), and silver-assisted surfactant mediated gold nanorods with aspect
ratios of approximately 2.85 (see Table 1) with the longitudinal plasmon peak
at 764 nm. The anti-HER2mouse monoclonal antibody (mAb) (Immunicon, USA) was
chosen as the targeting moiety. The antibody designated as HER81 recognizes
Human EGF receptor 2, HER2. HER2, also called erbB2, is a member of the
epidermal growth factor receptor (EGFR) family and is overexpressed in 20–40%
of humanbreast cancers [20].
Table 1
Mean aspect
ratios, lengths, widths, and longitudinal plasmon peaks for nanorods
synthesized using the silver-assisted growth method.
Sample
Volume of AgNO3 (
μL)
Aspect ratio (R)
Length (nm)
Width (nm)
LP band (nm)
1
50
2.3±0.3
44.8±4.1
19.8±2.9
675
2
100
2.85±0.6
45.1±5.5
15.8±3.1
764
3
150
3.0±0.6
41.7±3.9
13.9±2.3
788
4
200
3.1±0.5
52.0±4.6
16.8±2.8
831
5
250
3.6±0.6
51.0±4.4
14.1±2.1
850
In general, for optimum conjugation, it is recommended
that the pH of the antibody and gold sol be maintained at or slightly higher
than the isoelectric point (pI) of the antibody [21]. The isoelectric (pI) point of HER81 mAb was
determined using the Pharmacia PhastSystem isoelectric focusing (IEF). The pH
of the antibody was adjusted with dialysis in 5mM sodium acetate buffer and the
pH of the colloidal gold was adjusted with 0.1 M KOH, to approximately 0.5 pH
units above this value.Next, the minimum protecting amount of antibody to be
used for the conjugation is determined. This is the amount of protein that is
required to maintain colloidal stability of the conjugated NPs upon addition of
NaCl [21] as judged by
colorimetric analysis; as long as the conjugated NPs turns blue, particle
aggregation takes place implying that the amount of protein is not sufficient
to stabilize the suspension. By trial, different amounts of antibody are added
to samples of the gold sol, gently mixed, and allowed to stand at room
temperature for 2 minutes. Spectroscopic analysis reveals which sample remains
stable; the minimum amount of protein added is then ascertained and is used for
subsequent conjugation of the gold sol.To block the free surfaces on the gold, 10% bovineserum albumin (BSA) in dialyzed buffer (sodium acetate), maintained at the same
pH as the antibody solution, is used. The BSA was added to the conjugate to a
final concentration of 1%and was allowed to incubate for 5 minutes. The
resultant was then centrifuged for 30 minutes at 12000g to remove excess
protein and incompletely stabilized particles. The resulting pellet is
dispersed in phosphate buffered saline (PBS) containing 1% BSA and stored at 4°C.
2.4. Cell culture and cell-bioconjugate
incubation
The HER2 positive mammary adenocarcinoma (SKBR3) cell
line was used as a positive cell line; Chinese hamster ovary (CHO) cells were
used as an HER2 negative cell line. The cells were cultured in RPMI 1640 medium
(Invitrogen) supplemented with glutamine, 10% FBS (Fetal Bovine Serum) with
antibiotics. Cells were maintained in an incubator at 37°C and 5% CO2.The cells were detached from the tissue culture plate
using trypsin. The cells were replated onto 12 mm glass cover slips in a 6-well
tissue culture plate, and allowed to grow for 2 days at 37°C, 5% CO2.
When the cells grew to 80% confluence on the cover slips, the cells were rinsed
with phosphate buffered saline (PBS) and fixed in 4% paraformaldehyde (PFA) for
15 minutes at room temperature.
2.5 Immunostaining and confocal
microscopy
After fixation, immunostaining was performed on the
cells. The cells were incubated with 100
μL of conjugated
gold nanoparticles at a concentration of
9.7 × 1010 particles per
mL for 2 hours followed by silver enhancement performed using a silver-staining
kit (Aurion, Wageningen, The Netherlands).Confocal microscopy reflection images of the cells on
cover slips were recorded on a Zeiss LSM 510 confocal laser scanning microscope
using a C-Apochromat 63 X/1.4 numerical aperture (NA) water-immersion
objective. An excitation wavelength of 543 nm was chosen and reflection images
recorded using a 500–550 nm bandpass filter. All images were acquired with
pinhole diameters of 178
μm. Care was
taken to ensure that the excitation intensity as well as detector and amplifier
gains were maintained at the same values for all images to facilitate
comparison.
3. RESULTS
3.1 Synthesis of gold nanorods
We used seed particles within about 8 minutes of
formation in the subsequent growth phase. The optical extinction spectrum of
8-minute-aged seed is shown in Figure 1.
Figure 1
Optical
extinction spectrum of preformed 8-minute-aged CTAB-capped gold nanospheres as
seed for nanorod synthesis.
Figure 2 shows the extinction spectrum and HR-SEM
image of the nanorods synthesized using 50
μL AgNO3 in the
growth solution. The peak at 675 nm can be attributed to longitudinal plasmon
resonance and the peak in the vicinity of 516.5 nm to transverse plasmon
resonance.
Figure 2
Gold nanorods synthesized using 50 μL of silver nitrate in growth solution. (a) Optical extinction spectrum showing the transverse plasmon peak at 516.5 nm and the longitudinal plasmon peak at 675
nm. The amplitude of the longitudinal plasmon peak is higher than transverse
plasmon peak which indicates the formation of high yield of nanorods compared
to spheres. (b) High-resolution scanning electron microscope (SEM) image of
gold nanorods showing high monodispersity. Few nanospheres are observed.
Examination of the SEM image and determination of the
mean sizes confirm that the NPs produced consist of monodisperse nanorods of
aspect ratio of
2.3 ± 0.3, with a small number of large spheres; the latter's
extinction peak coinciding with the transverse plasmon band of the nanorods.
Figure 3 shows the extinction spectrum and the SEM image for the sample
produced using 250
μL of silver
nitrate. It is seen that the longitudinal plasmon band is shifted to 850 nm.
Sizing from the SEM image yields an average aspect ratio of
3.6 ± 0.6. Figure 4 shows the size distribution of the 2
specimens.
Figure 3
Gold nanorods synthesized using 250 μL of silver
nitrate in growth solution. (a) Optical extinction spectrum showing the
transverse plasmon peak at 516 nm and the longitudinal plasmon peak at 850 nm.
(b) High-resolution scanning electron microscope (SEM) image.
Figure 4
Histograms of gold nanorod aspect ratios synthesized with (a) 50
μL silver nitrate, mean aspect ratio of 2.3 ± 0.3 (mean length
44.8 ± 4.1nm, mean width 19.8 ± 2.9 nm); and with (b) 250
μL silver nitrate, mean aspect ratio of 3.6 ± 0.6 (mean length
51.0± 4.4 nm, mean width 14.1±2.1).
The values of the molar extinction coefficient for the
2 cases above are 3.3±0.3×109 and
5.5±0.3×109 M−1 cm−1 obtained by extrapolation of
the data as reported in [19]. With this, we arrive at the concentration of the
nanorods with peak at 675 nm as
4.3±0.3×1011 NR/mL; for
nanorods with the peak at 850 nm as 1.3±0.7×1011 NR/mL.Figure 5 shows the consolidated normalized extinction
spectra of 5 nanorod solutions, having identical growth solutions with varying
silver nitrate volumes. The spectra were normalized to the peak at 516 nm,
which is due to a combination of the transverse plasmon resonance of the
nanorods and the signature peak of gold nanospheres. It is seen that with
higher silver nitrate volumes the extent of red-shifting increases [22]. The details of the
observed changes in aspect ratios and plasmon bands are presented in Table 1.
Figure 5
Normalized
extinction spectra of gold nanorods with increasingly red-shifted longitudinal
plasmon bands, synthesized using 50, 100, 150, 200, and 250
μL of silver nitrate in the growth solution for
curves 1–5, respectively. Normalization of the spectra is done with respect to
the transverse plasmon peak amplitudes.
3.2 Bioconjugation of gold nanospheres and gold
nanorods
A signature for successful binding of protein to gold
NPs is a red-shifted and amplitude reduced plasmon band. Both these effects are
due to the formation of the inhomogeneous layer of protein on the gold particle
surface that leads to the modification of refractive index of the embedding
medium.Figure 6(a) shows the extinction spectrum of gold
nanospheres before and after incubation with HER81. Figure 6(b) is the
corresponding situation with gold nanorods before and after incubation with the
HER81 mAb. In both cases, the characteristic red-shift in the extinction peak
of the plasmon bands is seen.
Figure 6
Extinction spectra before and after incubation of
HER81 with (a) gold nanospheres, (b) gold nanorods. In both cases, a red shift
in plasmon band(s) occurs after incubation with the antibody signifying
successful bioconjugation.
Not too much should be read into the amplitude changes
of the extinction spectra since centrifugation of the bioconjugate to remove
unbound protein, redispersion in water, and other procedures results in a
change in the concentration of the NPs used for spectroscopy.Figure 7(a) show confocal reflectance image (on left)
and bright field image (on right) of the HER81 mAb/gold sphere conjugates
incubated with SKBR3 cells. As discussed in the experimental section, silver
enhancement was used by which silver is reduced onto the gold particles forming
large clusters around 500 nm in size. This then enables visualization under the
microscope. The HER2 receptors are localized to the cell membranes of SKBR3
cells. The high intensities in both images at the cell membrane are then
evidence of the preservation of the functionality of the antibody and also
illustrate successful conjugation. The images in Figure 7(b), which show the
situation with the negative control using the CHO cells, display no such
accumulation of gold particles. Also, adding nonantibody conjugated gold NPs to
the SKBR3 cells did not result in accumulation of the nanorods, indicating the
specificity of the HER81 antibody-nanorod conjugate (data not shown).
Figure 7
Confocal reflectance images (left) and bright field
images (right) of (a) SKBR3 cells incubated with silver-stained HER81/gold
sphere conjugates, (b) CHO cells under the same conditions. Care was taken to
maintain the same acquisition parameters in both cases. The silver-stained
bioconjugates are detected at the cell membranes of SKBR3 cells where HER2 is
localized. This indicates successful conjugation and retention of functionality
of the antibody after conjugation. No such accumulation of HER81/gold sphere
conjugates is demonstrated in HER2 negative CHO cells.
Figures 8(a) and 8(b) are the results of the
corresponding controls using the HER81 mAb/gold nanorods.
Figure 8
Corresponding images as in Figure 7 for bioconjugates consisting of
silver-stained HER81/gold nanorod conjugates incubated with (a) SKBR3 cells and
(b) CHO cells. Care was taken to maintain the same acquisition parameters in
both cases. The bioconjugates are accumulated at the cell membranes of SKBR3
cells where HER2 is localized. As expected, no such accumulation takes place in
the case of HER2 negative CHO cells.
4. DISCUSSION
4.1 Gold nanorod synthesis
The end products of the seed-mediated growth protocols
are crucially dependent on the nature of the seed, upon their size and upon the
capping agents used. Additionally, the constituents and their concentrations in
the growth solution influence the outcome of the synthesis products. The
addition of silver ions in the growth solution and the use of preformed CTAB
stabilized seed in the protocol of Nikoobakht and El-Sayed [17] produced not only a high
yield of monodisperse nanorods but fine tunability of aspect ratios.There are many unanswered questions regarding the
mechanism of formation of gold nanorods using the silver-assisted protocol and
this has been the topic of several studies [15, 17–19]. Recent reports of Orendorff and Murphy [19], and Liu and Guyot-Sionnest
[23] provide some
insights into the mechanisms that could be involved in the synthesis. It is
postulated that silver ions are reduced by ascorbic acid even though it is a
weak reducing agent, by the phenomenon of underpotential deposition (UPD). This
is reduction of silver in monolayers on the growing gold nanorod surface at a
potential less than the standard reduction potential [19]. The deposition is not
uniform on the gold surface but occurs faster on the sidewalls compared with
the end faces. Remarkably, the sidewalls in the case of nanorods produced with
silver assistance using CTAB protected seed bear Au{110} faces, while the end
faces have Au{100} faces. This is in contrast to the rods prepared by using
citrate-capped seed without Ag+. This faster passivation of the sidewalls is
followed by CTAB binding possibly via bromide ions. This inhibits the reduction
of gold, which deposits on the end faces. Ultimately, the end faces are also
stabilized preventing the formation of very long nanorods. The model claims
also to explain the increase in aspect ratio of the nanorods produced with
higher concentration of silver ions used, by proposing that higher UPD of
silver monolayers occur on the sidewalls which one assumes reducing the width
of the nanorods thus increasing the aspect ratios [19].Indeed, we observe some phenomena that are consistent
with the above model. We are able to synthesize gold nanorods only up to an
aspect ratio of 3.6, as shown in Figure 3. Addition of higher volumes of silver
nitrate produces no further increase in the aspect ratios of the particles.
These particles have an average length of 51 nm. This supports the idea that
ultimately complete passivation of the entire nanorod surface occurs preventing
further gold deposition even though the reagents have not been exhausted.
Further, we observe that nanorods that are made with increasing Ag+ volumes
have smaller diameters with the lengths practically unchanged or only slightly
increasing (see Table 1). The above model can also explain this. It must be
mentioned that the model does not have an appealing explanation regarding the
ability to tune the aspect ratios so precisely by Ag+ variation. It is very
likely that the model will have to undergo refinements or even major changes
before it is universally accepted.
4.2 Gold nanoparticle—antibody conjugation
The noncovalent conjugation of proteins to colloidal gold is usually due to a combination of electrostatic and hydrophobic interactions. Citrate-capped gold NPs are negatively charged due to a layer of negative
citrate ions. Positively charged amino groups of the antibody will be attracted
to the gold surface, and when the protein comes close enough for binding, the
hydrophobic pockets of the protein will make contact and bind with the gold
[24]. A general
guideline to optimize the bioconjugation is that the pH of the antibody and the
gold sol must be maintained at or slightly above the isoelectric point of the
antibody [24].
Following this, procedure for citrate-capped gold nanospheres with the HER81
antibody resulted in good bioconjugation as shown by the spectroscopy and
bioactivity studies (Figure 7).With nanorods, the situation is more complex as
compared with nanospheres. The sidewalls of the nanorods are expected to be
stabilized with a bilayer of CTAB, which imparts a positive charge to the gold.
Huang et al. [25]
first changed the positively charged surface to a negatively charged one by
exposing the nanorods to poly(styrenesulfonate) PSS polyelectrolyte solution.
The PSS-capped nanorods were then treated in the same way as in Section
2.3 with the conjugation being done with anti-EGFR monoclonal antibodies.Zeta potentials of the gold nanorod solution as
originally prepared were determined to be
+55 mV.
Centrifugation to remove the excess unbound CTAB and redispersion of the rods
in water saw a reduction in the zeta potential to
+7.5 mV, which also
points to a low stability. We surmise that inspite of the net positive charge,
the unpassivated end faces would be negatively charged due to the presence of
AuCl−2 ions [21]. We
therefore performed the same protocol (as in Section 2.3) and found that the
bioconjugation indeed was achieved as demonstrated by the red-shifted extinction
spectra as seen in Figure 6. Further, confocal microscopy successfully detected
the bioconjugates on the HER2 positive cell line (Figure 8), indicating the
success of the conjugation.We believe that the mechanism of conjugation is the
same as that in the case of gold nanospheres that is electrostatic and
hydrophobic physisorption. It is also likely that at the pH at which the
antibody is maintained, the Fc fragment of the antibody that is rich in
positively charged amino acids such as lysine will bind to the negatively
charged chloride ion layer on the exposed end faces of the rods. We intend to
perform studies that will elucidate this aspect. Further, we will perform the
protocol of first capping the nanorods with PSS for example, and then comparing
the antigen binding affinity constants of the bioconjugates from the two
methods.
4.3 Potential contrast enhancing
applications
The scattering and absorption bands of the synthesized
nanorods span the wavelength regime between 675–850 nm that is of interest to
optical imaging. This occupies the most important part of the “optical imaging
window” where light penetration in tissue is high due to reduced scattering
and absorption coefficients. Optical imaging techniques (Table 2) that rely on
scattering and/or absorption contrast to detect pathological tissue could
benefit from the use of such nanoparticles with or without targeting
capability.
Table 2
Important optical imaging techniques that utilize absorption and scattering contrasts in biology and medicine.
Technique
Imaging depth
Imaging resolution
Mechanism
Typical imaging applications
Confocal microscopy [1]
500 μm
> 250 nm
Scattering / absorption
Tissue surfaces
Two-photon microscopy [2]
800 μm
> 250 nm
Absorption
Tissue surfaces
Optical coherence tomography [3]
2 mm
1 μm
Scattering
Surfaces/subsurfaces of tissue
Diffuse optical tomography [4]
> 20 mm
≈ 10 % depth
Scattering/absorption
Small animal;human breast and brain
Photoacoustic imaging [5]
> 20 mm
< 1 mm(detector bandwidth limited)
Absorption
Subsurface to deep imaging;small animal; human breast
Our goal is to employ these particles as contrast
agents for photoacoustic cancer imaging, which has been proposed earlier by
Oraevsky and coworkers [26, 27]. Photoacoustic imaging relies on optical absorption
for its signals. When photons are absorbed, nonradiative de-excitation of the
absorbed optical energy takes place with the release of localized heat. The
local thermal expansion that results produces pressure transients [5]. When illuminated with
pulsed laser light, a tumor site by virtue of its higher absorption with respect
to the healthy background tissue, due to angiogenesis [28], will act as a source of
bipolar photoacoustic pulses. This ultrasound propagates with minimal
distortion to the surface where it is detected using appropriate wideband
detectors. The time-of-flight, amplitude, and peak-peak time of the bipolar PA
pulse possess information regarding the location, absorption, and dimensions of
the source, thereby permitting a reconstruction of the tumor site [29, 30].It is known that the NIR optical absorption contrast
of tumors versus healthy tissue, measured using optical mammographic methods,
is between 1.5 and 3. Clinical trials of optical mammography are being conducted
worldwide but at present, it seems implausible that intrinsic contrast alone
will provide sufficient sensitivity and specificity, and targeted contrast
enhancement is likely to be required [31]. Since the same contrast mechanism of optical
absorption is operative in photoacoustic imaging as well, a similar conclusion
may be anticipated.An impression of the feasibility of using the nanorods
synthesized for contrast enhancement is now discussed. The absorption
cross-section of a nanorod at a wavelength, say 800 nm, is estimated using
discrete dipole approximation (DDSCAT) simulations [32, 33] as
C
abs = 2.8 × 10−14 m2 . A typical average optical
absorption coefficient for an invasive ductal carcinoma is
μ
a = 0.008 mm−1 at 800 nm. In order to achieve
contrast enhancement, a certain number density of gold nanorods is required to
exhibit higher absorption than the intrinsic value and may be calculated
as
This gives
ρ
NR = 2.8 × 108 NR/cm3 . Further photoacoustic signals
can be enhanced by a thermal nonlinearity mechanism to 3 orders of magnitude
higher [34], then the
modified number density of nanorods required is only
ρ
NR = 2.8 × 105 NR/cm3 .Published studies report that most tumour cell
types express from
2 × 104 to
20 × 104 ErbB2
receptors/cell [12].
Let us assume arbitrarily that
2 × 103 of these sites
per cell are occupied by conjugated nanorods. Further, if we assume that 1% of
cells at a tumor site overexpress HER2 results in a figure of
2 × 106 cancer cells/cm3
. This will then lead to an
estimation of the density of binding sites of the order of
109 cm−3 . Comparison of
ρ
NR and the
estimated figure of density of binding sites leads us to believe that contrast
enhancement will be possible.We intend to test these molecular probes in small
animal photoacoustic imaging. Contrast enhancement with untargeted PEG-coated
nanoparticles will be studied. Accumulation of the contrast agent at the tumor
site will depend on enhanced permeation and retention (EPR). Active targeted
studies will follow, with conjugated nanoparticles administered to the animal
via the tail vein. In all studies, emphasis will be on ascertaining the
sensitivity/efficacy of the technique with and without contrast agent.
5. CONCLUSIONS
We have synthesized gold nanorods with optical
extinction peaks in the region from 675–850 nm making these eminently suited
for scattering and absorption contrast enhancements in optical imaging. We have
performed bioconjugation of these nanorods with HER81 antibodies, which bind
with high efficiency to HER2 receptors expressed by SKBR3breast carcinoma
cells. We demonstrated in fixed cell studies that the targeting functionality
of the antibody moiety remains viable. However, it must be mentioned that the
situation in vivo will be complex compared to the simplified situation in
vitro . Other unresolved issues remain at present. One of these is regarding
toxicity and cellular uptake of these particles in vivo . Further,
whether these molecular probes will be able to extravasate into the tumor
tissue through leaks in the vasculature has not yet been studied. These are
some lines of research that we intend to follow in the near future.
Authors: B J Tromberg; N Shah; R Lanning; A Cerussi; J Espinoza; T Pham; L Svaasand; J Butler Journal: Neoplasia Date: 2000 Jan-Apr Impact factor: 5.715
Authors: Alex W H Lin; Nastassja A Lewinski; Jennifer L West; Naomi J Halas; Rebekah A Drezek Journal: J Biomed Opt Date: 2005 Nov-Dec Impact factor: 3.170
Authors: Herbert Rinneberg; Dirk Grosenick; K Thomas Moesta; Jörg Mucke; Bernd Gebauer; Christian Stroszczynski; Heidrun Wabnitz; Michael Moeller; Bernhard Wassermann; Peter M Schlag Journal: Technol Cancer Res Treat Date: 2005-10
Authors: John A Copland; Mohammad Eghtedari; Vsevolod L Popov; Nicholas Kotov; Natasha Mamedova; Massoud Motamedi; Alexander A Oraevsky Journal: Mol Imaging Biol Date: 2004 Sep-Oct Impact factor: 3.488
Authors: Anton Liopo; André Conjusteau; Dmitri Tsyboulski; Boris Ermolinsky; Alexander Kazansky; Alexander Oraevsky Journal: J Nanomed Nanotechnol Date: 2012-08-03